| Mr James Leahy Sullivan, MD | |
|
680 E Fremont Medical Park Dr, Fremont, NE 68025-2309 | |
| (402) 727-1091 | |
| (402) 727-7628 |
| Full Name | Mr James Leahy Sullivan |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 23 Years |
| Location | 680 E Fremont Medical Park Dr, Fremont, Nebraska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538154141 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 23377 (Nebraska) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Methodist Fremont Health Home Care | Fremont, NE | Home health agency |
| Nye Home Health Care | Fremont, NE | Home health agency |
| Fremont Health Hospice | Fremont, NE | Hospice |
| Methodist Fremont Health | Fremont, NE | Hospital |
| The Nebraska Medical Center | Omaha, NE | Hospital |
| Dunklau Gardens | Fremont, NE | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Physicians Clinic Inc | 4880506062 | 497 |
News Archive
In findings that support a relationship between agricultural chemicals and Parkinson's disease, two groups of researchers have found new evidence that loss of DJ-1, a gene known to be linked to inherited Parkinson's disease, leads to striking sensitivity to the herbicide paraquat and the insecticide rotenone.
UCB has announced pivotal RAPID 1 (RA PreventIon of structural Damage) data published in Arthritis & Rheumatism shows CIMZIA (certolizumab pegol), the only PEGylated anti-TNF (Tumour Necrosis Factor alpha), together with methotrexate (MTX), rapidly reduced symptoms of disease and inhibited progression of joint damage in adult patients with active rheumatoid arthritis (RA), with sustained results for up to one year.
After recent consultation with the FDA in November 2010, Merrion is preparing for its Phase III study for Orazol. If successful, the Phase III study will allow a new drug application for Orazol to be made under the FDA's abbreviated approval procedure section 505(b)(2) using a single Phase III study. The study will compare Orazol against placebo as an adjuvant breast cancer treatment with a primary endpoint of Disease Free Survival of patients with breast cancer.
MicroStockProfit.com announces an investment report featuring BioSphere Medical Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
› Verified 4 days ago
| Entity Name | Physicians Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821049156 PECOS PAC ID: 4880506062 Enrollment ID: O20031105000345 |
News Archive
In findings that support a relationship between agricultural chemicals and Parkinson's disease, two groups of researchers have found new evidence that loss of DJ-1, a gene known to be linked to inherited Parkinson's disease, leads to striking sensitivity to the herbicide paraquat and the insecticide rotenone.
UCB has announced pivotal RAPID 1 (RA PreventIon of structural Damage) data published in Arthritis & Rheumatism shows CIMZIA (certolizumab pegol), the only PEGylated anti-TNF (Tumour Necrosis Factor alpha), together with methotrexate (MTX), rapidly reduced symptoms of disease and inhibited progression of joint damage in adult patients with active rheumatoid arthritis (RA), with sustained results for up to one year.
After recent consultation with the FDA in November 2010, Merrion is preparing for its Phase III study for Orazol. If successful, the Phase III study will allow a new drug application for Orazol to be made under the FDA's abbreviated approval procedure section 505(b)(2) using a single Phase III study. The study will compare Orazol against placebo as an adjuvant breast cancer treatment with a primary endpoint of Disease Free Survival of patients with breast cancer.
MicroStockProfit.com announces an investment report featuring BioSphere Medical Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
› Verified 4 days ago
| Entity Name | Memorial Health Care Systems |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699845016 PECOS PAC ID: 3274528989 Enrollment ID: O20040420000611 |
News Archive
In findings that support a relationship between agricultural chemicals and Parkinson's disease, two groups of researchers have found new evidence that loss of DJ-1, a gene known to be linked to inherited Parkinson's disease, leads to striking sensitivity to the herbicide paraquat and the insecticide rotenone.
UCB has announced pivotal RAPID 1 (RA PreventIon of structural Damage) data published in Arthritis & Rheumatism shows CIMZIA (certolizumab pegol), the only PEGylated anti-TNF (Tumour Necrosis Factor alpha), together with methotrexate (MTX), rapidly reduced symptoms of disease and inhibited progression of joint damage in adult patients with active rheumatoid arthritis (RA), with sustained results for up to one year.
After recent consultation with the FDA in November 2010, Merrion is preparing for its Phase III study for Orazol. If successful, the Phase III study will allow a new drug application for Orazol to be made under the FDA's abbreviated approval procedure section 505(b)(2) using a single Phase III study. The study will compare Orazol against placebo as an adjuvant breast cancer treatment with a primary endpoint of Disease Free Survival of patients with breast cancer.
MicroStockProfit.com announces an investment report featuring BioSphere Medical Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
› Verified 4 days ago
| Entity Name | Community Hospital Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588771158 PECOS PAC ID: 9133101629 Enrollment ID: O20040607001378 |
News Archive
In findings that support a relationship between agricultural chemicals and Parkinson's disease, two groups of researchers have found new evidence that loss of DJ-1, a gene known to be linked to inherited Parkinson's disease, leads to striking sensitivity to the herbicide paraquat and the insecticide rotenone.
UCB has announced pivotal RAPID 1 (RA PreventIon of structural Damage) data published in Arthritis & Rheumatism shows CIMZIA (certolizumab pegol), the only PEGylated anti-TNF (Tumour Necrosis Factor alpha), together with methotrexate (MTX), rapidly reduced symptoms of disease and inhibited progression of joint damage in adult patients with active rheumatoid arthritis (RA), with sustained results for up to one year.
After recent consultation with the FDA in November 2010, Merrion is preparing for its Phase III study for Orazol. If successful, the Phase III study will allow a new drug application for Orazol to be made under the FDA's abbreviated approval procedure section 505(b)(2) using a single Phase III study. The study will compare Orazol against placebo as an adjuvant breast cancer treatment with a primary endpoint of Disease Free Survival of patients with breast cancer.
MicroStockProfit.com announces an investment report featuring BioSphere Medical Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
› Verified 4 days ago
| Entity Name | Jennie M Melham Memorial Medical Center Inc |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1538232244 PECOS PAC ID: 5799766440 Enrollment ID: O20071129000446 |
News Archive
In findings that support a relationship between agricultural chemicals and Parkinson's disease, two groups of researchers have found new evidence that loss of DJ-1, a gene known to be linked to inherited Parkinson's disease, leads to striking sensitivity to the herbicide paraquat and the insecticide rotenone.
UCB has announced pivotal RAPID 1 (RA PreventIon of structural Damage) data published in Arthritis & Rheumatism shows CIMZIA (certolizumab pegol), the only PEGylated anti-TNF (Tumour Necrosis Factor alpha), together with methotrexate (MTX), rapidly reduced symptoms of disease and inhibited progression of joint damage in adult patients with active rheumatoid arthritis (RA), with sustained results for up to one year.
After recent consultation with the FDA in November 2010, Merrion is preparing for its Phase III study for Orazol. If successful, the Phase III study will allow a new drug application for Orazol to be made under the FDA's abbreviated approval procedure section 505(b)(2) using a single Phase III study. The study will compare Orazol against placebo as an adjuvant breast cancer treatment with a primary endpoint of Disease Free Survival of patients with breast cancer.
MicroStockProfit.com announces an investment report featuring BioSphere Medical Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
› Verified 4 days ago
| Entity Name | Community Hospital Association |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1841204500 PECOS PAC ID: 9133101629 Enrollment ID: O20100908000859 |
News Archive
In findings that support a relationship between agricultural chemicals and Parkinson's disease, two groups of researchers have found new evidence that loss of DJ-1, a gene known to be linked to inherited Parkinson's disease, leads to striking sensitivity to the herbicide paraquat and the insecticide rotenone.
UCB has announced pivotal RAPID 1 (RA PreventIon of structural Damage) data published in Arthritis & Rheumatism shows CIMZIA (certolizumab pegol), the only PEGylated anti-TNF (Tumour Necrosis Factor alpha), together with methotrexate (MTX), rapidly reduced symptoms of disease and inhibited progression of joint damage in adult patients with active rheumatoid arthritis (RA), with sustained results for up to one year.
After recent consultation with the FDA in November 2010, Merrion is preparing for its Phase III study for Orazol. If successful, the Phase III study will allow a new drug application for Orazol to be made under the FDA's abbreviated approval procedure section 505(b)(2) using a single Phase III study. The study will compare Orazol against placebo as an adjuvant breast cancer treatment with a primary endpoint of Disease Free Survival of patients with breast cancer.
MicroStockProfit.com announces an investment report featuring BioSphere Medical Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
› Verified 4 days ago
| Entity Name | Methodist Fremont Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235618216 PECOS PAC ID: 7911258520 Enrollment ID: O20181017000110 |
News Archive
In findings that support a relationship between agricultural chemicals and Parkinson's disease, two groups of researchers have found new evidence that loss of DJ-1, a gene known to be linked to inherited Parkinson's disease, leads to striking sensitivity to the herbicide paraquat and the insecticide rotenone.
UCB has announced pivotal RAPID 1 (RA PreventIon of structural Damage) data published in Arthritis & Rheumatism shows CIMZIA (certolizumab pegol), the only PEGylated anti-TNF (Tumour Necrosis Factor alpha), together with methotrexate (MTX), rapidly reduced symptoms of disease and inhibited progression of joint damage in adult patients with active rheumatoid arthritis (RA), with sustained results for up to one year.
After recent consultation with the FDA in November 2010, Merrion is preparing for its Phase III study for Orazol. If successful, the Phase III study will allow a new drug application for Orazol to be made under the FDA's abbreviated approval procedure section 505(b)(2) using a single Phase III study. The study will compare Orazol against placebo as an adjuvant breast cancer treatment with a primary endpoint of Disease Free Survival of patients with breast cancer.
MicroStockProfit.com announces an investment report featuring BioSphere Medical Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr James Leahy Sullivan, MD 19321 Spyglass Ct, Plattsmouth, NE 68048-7153 Ph: (402) 296-2868 | Mr James Leahy Sullivan, MD 680 E Fremont Medical Park Dr, Fremont, NE 68025-2309 Ph: (402) 727-1091 |
News Archive
In findings that support a relationship between agricultural chemicals and Parkinson's disease, two groups of researchers have found new evidence that loss of DJ-1, a gene known to be linked to inherited Parkinson's disease, leads to striking sensitivity to the herbicide paraquat and the insecticide rotenone.
UCB has announced pivotal RAPID 1 (RA PreventIon of structural Damage) data published in Arthritis & Rheumatism shows CIMZIA (certolizumab pegol), the only PEGylated anti-TNF (Tumour Necrosis Factor alpha), together with methotrexate (MTX), rapidly reduced symptoms of disease and inhibited progression of joint damage in adult patients with active rheumatoid arthritis (RA), with sustained results for up to one year.
After recent consultation with the FDA in November 2010, Merrion is preparing for its Phase III study for Orazol. If successful, the Phase III study will allow a new drug application for Orazol to be made under the FDA's abbreviated approval procedure section 505(b)(2) using a single Phase III study. The study will compare Orazol against placebo as an adjuvant breast cancer treatment with a primary endpoint of Disease Free Survival of patients with breast cancer.
MicroStockProfit.com announces an investment report featuring BioSphere Medical Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
› Verified 4 days ago
Dr. Andrea Vermaas, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 350 W 23rd St, Fremont, NE 68025 Phone: 402-721-7077 Fax: 402-753-6020 | |
Dr. Robin J. Bernard, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2740 N Clarkson St, Fremont, NE 68025 Phone: 402-721-0951 | |
Dr. Milo Victor Anderson, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 350 W 23rd St, Suite D, Fremont, NE 68025 Phone: 402-721-8800 Fax: 402-753-6096 | |
Luke Lansman, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 680 E Fremont Medical Park Dr, Fremont, NE 68025 Phone: 402-815-7120 | |
Dr. Matthew A Beacom, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1625 E Military Ave, Fremont, NE 68025 Phone: 402-721-8830 Fax: 402-721-8840 | |
Doralia Yanely Flores, FNP Family Medicine Medicare: Medicare Enrolled Practice Location: 410 E 22nd St Ste 1, Fremont, NE 68025 Phone: 402-727-7979 Fax: 402-727-9306 |